180 related articles for article (PubMed ID: 21153753)
1. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.
Quartino AL; Friberg LE; Karlsson MO
Invest New Drugs; 2012 Apr; 30(2):833-45. PubMed ID: 21153753
[TBL] [Abstract][Full Text] [Related]
2. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
3. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
[TBL] [Abstract][Full Text] [Related]
4. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
[TBL] [Abstract][Full Text] [Related]
5. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
Netterberg I; Nielsen EI; Friberg LE; Karlsson MO
Cancer Chemother Pharmacol; 2017 Aug; 80(2):343-353. PubMed ID: 28656382
[TBL] [Abstract][Full Text] [Related]
6. [Effect of G-CSF (nartograstim) on neutropenia (leukopenia) induced by taxane in metastatic breast cancer--time-course changes in neutrophil and leukocyte counts].
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):815-9. PubMed ID: 11432350
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
9. Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
Friberg LE; Brindley CJ; Karlsson MO; Devlin AJ
Eur J Clin Pharmacol; 2000 Nov; 56(8):567-74. PubMed ID: 11151746
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.
Kathman SJ; Williams DH; Hodge JP; Dar M
Cancer Chemother Pharmacol; 2009 Feb; 63(3):469-76. PubMed ID: 18443793
[TBL] [Abstract][Full Text] [Related]
12. [Proposal of a novel dosing schedule of docetaxel by using alpha1-acid glycoprotein as an index].
Ozawa K; Minami H; Sato H
Yakugaku Zasshi; 2009 Dec; 129(12):1565-72. PubMed ID: 19952538
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic and pharmacodynamic analysis for time courses of docetaxel-induced neutropenia in Japanese cancer patients.
Ozawa K; Minami H; Sato H
Cancer Sci; 2007 Dec; 98(12):1985-92. PubMed ID: 17888031
[TBL] [Abstract][Full Text] [Related]
14. Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats.
Kobuchi S; Ito Y; Hayakawa T; Kuwano S; Baba A; Shinohara K; Nishimura A; Shibata N; Takada K
Xenobiotica; 2014 Sep; 44(9):804-18. PubMed ID: 24650147
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
[TBL] [Abstract][Full Text] [Related]
16. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer.
Dandamudi UB; Adams LM; Johnson B; Bauman J; Morris S; Murray S; Webb RT; Gartner E; Hohl R; Lewis LD
Cancer Chemother Pharmacol; 2011 Apr; 67(4):783-90. PubMed ID: 20556613
[TBL] [Abstract][Full Text] [Related]
18. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
Koolen SL; Oostendorp RL; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2010 May; 69(5):465-74. PubMed ID: 20573082
[TBL] [Abstract][Full Text] [Related]
20. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]